Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.

• By

• October 1, 2026

• 4 min

• Dana-Farber